Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eravacycline vs moxifloxacin in community-acquired bacterial pneumonia
CTR20213108Phase 3Terminated
- Sponsor
- Everest Medicines
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eravacycline in community acquired pneumonia (CAP) (2 arms), sponsored by Everest Medicines. Primary endpoint: Clinical efficacy in mITT population at TOC visit. Started Dec 2021; status: terminated.
02
Drugs
eravacycline
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on CTR20213108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213108.